Sex: F
Vaccine: COVID19
Symptoms: Discomfort
Clinical narrative: it felt like the needle went on her nerve and that it was not a pleasant experience on either occasion; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A female patient in her 70's received bnt162b2 (BNT162B2), intramuscular (Batch/Lot number: unknown) as dose 1, 0.3 ml single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DISCOMFORT (non-serious), outcome "unknown", described as "it felt like the needle went on her nerve and that it was not a pleasant experience on either occasion".  Additional information: She received the 2nd dose of the Pfizer covid vaccine. The nurse gave it to her through the syringe which had a couple of bubbles that were left in there. The amount of the vaccine looked like a small amount. When she injected her, the patient jerked her arm. Caller also reports that on the 1st injection it felt like the needle went on her nerve and that it was not a pleasant experience on either occasion. The patient asked if Pfizer provided a statement on the need for a booster dose (3rd dose) and Is Pfizer investigating the need for a booster dose. It was replied that The need for a booster dose of Pfizer-BioNTech COVID-19 vaccine based on duration of protection or impact of variant strains has not yet been determined. On February 25, Pfizer and BioNTech announced they initiated an evaluation of the safety and immunogenicity of a potential third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the effect of a booster on immunity against COVID-19 caused by the currently circulating and potential newly emerging variants. It is important to have a vaccine technology that allows us to both provide boosting doses if needed and to address potential changes in the virus itself if a new variant emerges that the vaccine does not protect against.  While we have not seen any evidence that the circulating variants result in a loss of protection provided by our vaccine in our laboratory studies, we are taking multiple steps to be ready in case a strain becomes resistant to the vaccine.  The administration of more than a 2-dose series of Pfizer BioNTech COVID-19 Vaccine is not approved. Pfizer is unable to make any recommendations regarding administration of a booster dose of Pfizer-BioNTech COVID-19 Vaccine; Pfizer does not suggest or recommend the use of the vaccine in any manner other than as described in the authorized EUA Prescribing Information (if US)/authorized product monograph. Note to frontline: This FAQ should only be used if someone specifically asks about the Pfizer statement on booster doses. For all other general inquiries about booster doses, please refer to the SRD titled "Administration of More Than a 2-Dose Series (Booster Dose)". Follow-up attempts not completed; information about lot/batch number cannot be obtained. No further information expected. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.